Figure 3. Results of Post Hoc Analyses of the Functional Assessment of Cancer Therapy Biological Response Modifiers (FACT-BRM) Trial Outcome Index (TOI) Score at Cycle 3 in Different Subgroups of Patients.

The blue boxes show the multivariable linear regression model–derived point estimates (adjusting for the stratification factors and the baseline score) for the group comparisons, and the horizontal lines show the corresponding 95% CIs. The bold, dashed vertical line indicates the 0 value representing no difference between groups, while the light dotted vertical line shows the value of 5 points between groups, in favor of patients randomized to the pembrolizumab arm and corresponding to the design-specified clinically meaningful difference in FACT-BRM TOI scores. HDI indicates high-dose interferon α 2b; PD-L1, programmed cell death ligand 1; QOL, quality of life.